Diaminocyclopentane-derived <i>O</i>-GlcNAcase inhibitors for combating tau hyperphosphorylation in Alzheimer's disease

Abstract

We developed potent and selective aminocyclopentane-derived inhibitors of human <i>O-N</i>-acetyl-β-D-glucosaminidase (OGA) implicated in Alzheimer's disease. For example compound 13 was a nanomolar OGA inhibitor with 92 000-fold selectivity over human HexB. It was non-toxic and increased protein <i>O</i>-GlcNAcylation in the culture of murine neural cells, showing new alternatives in the treatment of tauopathies.